Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has entered into an agreement relating to the acquisition of 100 percent of the shares in Cybergene AB, a Swedish company within the Level Bio AB (publ) group. The acquisition strengthens Devyser's customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser's gross profit and gross margin. The acquisition is subject to Devyser obtaining customary regulatory clearance.
Cybergene AB develops and markets products in the fields of aneuploidy and male infertility, complementing Devyser's existing product portfolio. The total purchase consideration amounts to appx. SEK 12.2 million and will be paid through newly issued shares in Devyser.
"We are very pleased to complete the acquisition of Cybergene AB. The transaction strengthens our product offering within aneuploidy and male infertility, while at the same time improving our gross margins," says Jan Wahlström, CEO, Devyser.
Cybergene was founded in 1995 and has demonstrated steady growth driven by a strong product offering and consistent market expansion. Devyser and Cybergene have been active in similar markets for many years, providing Devyser with in-depth knowledge of Cybergene's products and their strong customer acceptance.
Under the terms of the transaction agreement, the acquisition is conditional upon the receipt of all necessary clearances, approvals, decisions and other actions from the Inspectorate of Strategic Products under the Swedish Screening of Foreign Direct Investments Act. Closing of the acquisition is expected to occur on, and the acquisition is expected to be consolidated by, April 1, 2026 and is expected to have a positive impact on Devyser's gross profit as well as EBIT. The acquisition will be made through Devyser's wholly owned subsidiary and operating company Devyser AB.
The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller's claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares. The subscription price will correspond to the volume-weighted average price (VWAP) of the Devyser share on Nasdaq First North Premier Growth Market during the ten (10) trading days following and including the date of this announcement.
For more information, please contact:
Jan Wahlström, CEO
Email: ir@devyser.com
Telephone: +46 8 562 158 50
Sabina Berlin, CFO
Email: ir@devyser.com
Telephone: +46 8 562 158 50
About Devyser
Devyser is redefining how laboratories approach genetic testing. As your true one-stop shop, we offer streamlined solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency.?
Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes.?
We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta and maintain sales offices across Europe and the US.?
Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio.?
Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.?
Discover how we're shaping the future of lab diagnostics at www.devyser.com.?
This information is information that Devyser Diagnostics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-11 20:05 CET.
